COVID/HBO₂ Synopsis

Participants on the call

**UHMS BOD**
Nick Bird, MD - President
Marc Robins, DO, MPH - President-Elect

**UHMS Oxygen Therapy Committee**
Enoch Huang, MD, MPH - Chair
Enrico Camporesi, MD
William Dodson, MD, MPH
John Feldmeier, DO
Laurie Gesell, MD
Neil Hampson, MD
Richard Moon, MD - Immediate Past Chair
Heather Murphy-Lavoie, MD
Ben Slade, MD
Keith Van Meter, MD
Lindell Weaver, MD

**ACEP Section on UHM**
Richard Walker, MD - Chair
Davut Savaser, MD, MPH - Immediate Past Chair
Bruce Derrick, MD – Past Chair

**Research Groups**
Anders Kjellberg, MD - Karolinska Institute
Peter Lindholm, MD, PhD - UCSD
Ian Grover, MD - UCSD
Jay Duchnick, CHT - UCSD
Scott Gorenstein, MD - NY

**Invited Guests**
Nicole Harlan, MD
Kristi Ray, DO, MPH

**Introduction**
This is a synopsis of a conference call between invited members of the Hyperbaric Oxygen Therapy committee, the American College of Emergency Physicians’ Section on Undersea and Hyperbaric Medicine, and invited researchers with clinical trials on the use of HBO₂ and COVID-19. This is a synopsis of the discussion curated from a recording of the meeting.

**Background**
A case series of five patients has been circulated on the internet. This has drawn a lot of attention to the use of HBO₂ as a possible therapy for COVID-19. This has generated many questions that have been posed to the leadership of the UHMS.

**Synopsis of Chen Case Series**
This case series of five patients has not been published in the English literature, but may have been published in Chinese journals. This manuscript appears to have been translated into
English and disseminated informally to hyperbaric providers and policy members in the United States and abroad.

Study design
- 24-69 (mean 47.6) years old
- Chest CT showed typical pulmonary imaging changes of COVID-19
- Nucleic acid tests of SARS-CoV-2 were positive
- HBO2 was started after routine treatments failed to stop deterioration of condition
- HBO2 protocol
  - 2.0 ATA for first patient, then 1.6 ATA for subsequent patients
  - 90 minutes of oxygen breathing for first treatment, then 60 minutes after that

Results
- Clinical symptoms
  - Fever was not a persistent symptom
  - Always resolved after one course of routine therapy
  - Cough was not prominent symptom in these cases
  - All five patients had severe breathlessness
  - Symptoms of every case were “obviously mitigated” after first HBO2 treatment
  - Breathlessness (supine position) disappeared three days later
  - Digestive tract symptoms five days later
  - All the symptoms were basically relieved except for mild breathlessness (motion) complained by every patient

Diagnostic Changes
- SpO2
  - Each patient’s SpO2 increased day by day
  - Patients were transferred from the ward to the chamber without oxygen breathing
  - SpO2 outside the chamber reflects the true degree of hypoxemia under nature breathing state
  - Pre- vs. Post-HBO2 SpO2 shows daily improvement after HBO2 started

Table 1 the usage of oxygen therapy for 5 cases in the hospital

<table>
<thead>
<tr>
<th>patient</th>
<th>sex</th>
<th>age</th>
<th>before HBO treatment(d)</th>
<th>after first HBO treatment(d)</th>
<th>HBO(d)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nasal</td>
<td>Mask</td>
<td>Mech</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>69</td>
<td>2</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td>28</td>
<td>M</td>
<td>64</td>
<td>1</td>
<td>6</td>
<td>-</td>
</tr>
<tr>
<td>38</td>
<td>M</td>
<td>28</td>
<td>2</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>48</td>
<td>M</td>
<td>53</td>
<td>1</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>58</td>
<td>F</td>
<td>24</td>
<td>1</td>
<td>16</td>
<td>-</td>
</tr>
</tbody>
</table>

mean 47.6 1 12 - 1.4 8 4.6

NOTE: nasal = nasal oxygen breathing with a flow of 3-5L/min; Mask = mask oxygen breathing with a flow of 5-8L/min; Mech = non-invasive mechanical ventilation
ABG
- PaO₂ and SaO₂ were significantly increased after HBO₂ treatments (P<0.05)
- Non-significant rise in PaCO₂ suggests that patients had a trend of over-ventilation with an inefficient oxygen uptake before introducing HBO₂
- Elevated lactate before HBO₂ was attributed to systemic anaerobic metabolism due to progressive hypoxia

CBC
- A recent paper of COVID-19 reported significantly decreased lymphocyte count in non-survivors
- Amount of lymphocyte and LYM% of each patient was obviously elevated after HBO₂ treatments
- Suggests that routine systematic addition of daily HBO₂ would reduce mortality

Coagulation
- Fibrinogen (FIB) was increased before HBO₂, and significantly declined after HBO₂ treatment (P<0.05), as was D-Dimer (D-D).
- Activated partial thromboplastin time (APTT) was increased obviously after treatment.

Inflammatory markers
- Increased plasma CRP concentrations have been reported as an observed clinical feature of COVID-19
- CRP decreased after HBO₂

CT Finding
- All cases had previous imaging of mass shadows of high density in both lungs
- All Chest CTs obtained during or after HBO₂ showed significantly improved status
- Chest CT imaging suggested that the main pathological changes of COVID-19 pneumonia was inflammation of alveoli
- Patients had a loss of the lung gas exchange function larger than that of ventilatory function
- Decreased PaO₂ companied with decreased or normal PaCO₂
Claims

- It is suggested that HBO₂ provided the body an intermission of adequate aerobic metabolism, relieving the oxygen debt.
- Two HBO₂ treatments might be enough for correcting hypoxia of most patients with severe COVID-19.
- Subsequent daily HBO₂ treatment could basically avoid hypoxemia of COVID-19 pneumonia patients with SpO₂ lower than 70%.
- HBO₂ is a decisive treatment to the severe and critically ill patients with COVID-19 pneumonia.
- Suggests that early additional HBO₂ may stop the patient’s condition from deterioration when mask oxygen breathing could not prevent the decrease in SpO₂.
- Routinely adding daily HBO₂ would reduce mortality.

Comments and Critiques

- Selection criteria for hyperbaric treatment are not specified.
- The method of O₂ administration in the chamber is not described.
  - There is mention of the use of high-flow oxygen through a standard non-rebreather that would not be considered classic HBO₂ administration.
- The notion that a short period of HBO₂ will result in prolonged improvement in oxygenation is not substantiated by experience in other settings, where PO₂ decreases within minutes after decompression.
- In the case series, the decrease in lactate levels was statistically significant but was not clinically significant (only minimally elevated before HBO₂). Lactate itself does not say much about hypoxia since there are many reasons for elevation.
- The overall mortality of COVID-19 infection is less than 1%, and the usual course is clinical improvement. So, the observation that a small series of patients got better could perfectly well have been their normal course.
- Recommendations include a larger study/more case series that can draw conclusions regarding mortality and/or the possible therapeutic benefit of HBO₂.
- There is a question as to whether animal studies need to be completed since this case series has already shown that treatment was successful on humans.
- Although this case series did not show a level of evidence that one should go out and treat COVID-19 patients with HBO₂, it does warrant a larger organized trial that is well protocolized and well designed.
- This case study can be considered a feasibility report. HBO₂ has been successfully used to treat patients with COVID-19, and they did not acutely deteriorate in the chamber. The questions as to whether HBO₂ would induce pulmonary edema in these patients was not seen in this case series.
Rationale for HBO₂

Oxygenation

• PROs
  o COVID-19 disables the normal coupling of heme molecules therefore disrupting oxygenation. This functional hypoxia is similar to CO and cyanide poisoning, which are indications of HBO₂.
  o Patients with COVID-19-associated lung injury often present with severe hypoxemia and accumulated oxygen debt, in which HBO₂ could provide a reprieve.
  o Hyperbaric oxygen is likely to raise arterial PO₂ for the relatively brief period in which HBO₂ can be realistically administered.

• CONs
  o Arterial and tissue PO₂ rapidly decrease to baseline at the end of hyperbaric exposure; thus augmentation of blood and tissue oxygenation would only be transient

Attenuation of pulmonary inflammation

• PROs
  o There has been research to show that the polarization of macrophages reduces edema and in return can prolong the period of enhanced oxygenation.
  o HBO₂ could not only improve oxygen debt but also prevent the cytokine-mediated inflammatory state.

• CONs
  o The inflammatory issue is more theoretical in nature. We know that HBO₂ is anti-inflammatory in situations and indeed may be a mechanism of action. With COVID, there is no evidence for it yet.

Risks of HBO₂

• Pulmonary barotrauma
  o There is literature supporting that COVID-19 is presenting as an atypical ARDS with highly compliant lungs. There are discussions as to whether clinicians are causing lung injury secondary to the high pressures of ventilation.
  o Pulmonary barotrauma is unusual, provided any pneumothoraces have been identified and decompressed before initiating HBO₂

• Pulmonary oxygen toxicity
  o Extended exposure to above-normal oxygen partial pressures, or shorter exposures to very high partial pressures, can cause oxidative damage to cell membranes, which can lead to the collapse of the alveoli in the lungs. Tracheobronchitis and absorptive atelectasis can cause pulmonary edema, which would likely lead to acute deterioration in COVID-19 patients.

• Infection control
Measures that have been discussed include:
- Droplet precaution protocols
- Patients transported to HBO\textsubscript{2} with oxygen via non-rebreather mask
- All medical staff and hyperbaric technicians wear N95 masks and shields
- Air breaks at the discretion of the supervising physician
- Using a specific chamber for COVID-19 positive patients
- Consider having staff pressurize in separate lock chamber to decrease exposure

Future Research
- Questions to be answered
  - How many treatments?
    - Chen case series reported two treatments to have beneficial effect on patient outcomes
    - Treatments should be limited to while the patient is hospitalized. NYU’s protocol limits to a total of five treatments that can be extended for another five if clinically necessary.
  - What treatment pressure?
    - Chen case series used 2.0 ATA at 90 minutes for the first patient, and 1.6 ATA at 60 minutes for subsequent patients. There was no discussion as to why this specific protocol was chosen.
    - The NYU study will be treating patients at 2.0 ATA for 90 minutes.
    - Karolinska Institute/UCSD study will be treating patients at 2.4 ATA for 30 minutes.
  - How long for treatments?
    - Chen case series used 90 minutes for the first patient, and 60 minutes for subsequent treatments without explanation as to why.
    - NYU will be using 90 minutes.
    - Karolinska Institute/UCSD will be using 30 minutes; previous research conducted showed that gene expression changes in macrophages occurred within 15 minutes in healthy individuals.
  - How soon should HBO\textsubscript{2} be used?
    - There is currently no evidence to when HBO\textsubscript{2} should be trialed and how many treatments offered. Given the current situation of lack of ventilators, primary outcomes should include the prevention of respiratory failure and intubation.
    - However, this does not mean that HBO\textsubscript{2} would not work on intubated ICU patients.
    - Due to the presentation of COVID-19 patients with fulminant lung damage, timing of HBO\textsubscript{2} is critical and should be initiated within 3-10 days of symptoms onset if possible.
    - Protocols of current clinical trials focus on deteriorating but not yet intubated patients.
What is the outcome we want to effect?
- Averting mechanical ventilation
- Improvement of symptoms
- Reduced mortality
- Biochemical markers

Studies under way (see separate document listing all current studies under way)
- NYU
- Karolinska/UCSD
- Oschner
- NOLA

Position Statement
- No routine HBO2 for COVID respiratory failure
- IRB-approved studies welcome